Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years Over half of all women experience a uUTI in their lifetime, with approximately 30% suffering from a recurrent episode Approval based on data from the pivotal phase III EAGLE-2 and EAGLE-3 trials PHILADELPHIA / Mar 25, 2025 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved... Read More

Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults PHILADELPHIA / Feb 17, 2025 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY... Read More

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers GSK to pay up to $1.15 billion PLYMOUTH, Mass. /... Read More

DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination; benefit seen early and maintained through follow-up Data build on findings from DREAMM-7 and DREAMM-8 and support the potential for belantamab mafodotin combinations to become standard of care Belantamab... Read More

TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ: MDCX TSXV: MDCX) (the “Company”) is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. “We are thrilled to welcome Dr. Mehmud to our leadership team,” stated Dr. Raza Bokhari, Exec. Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical... Read More

Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD Two doses of vaccine in immunocompromised adults aged 18 and older elicited immune responses similar to one dose in healthy adults aged 50+ and with an acceptable safety profile In the US alone, adults aged 18-49 with at least one risk factor for RSV disease could exceed 21 million 1... Read More

GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk Safety and reactogenicity data are consistent with previous results from the phase III program GSK will continue to provide data on longer-term follow-up to help recommending bodies determine future revaccination schedules PHILADELPHIA / Oct 08, 2024 / Business Wire / GSK plc... Read More

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety profiles These data advance the science of co-administration of recommended adult vaccines PHILADELPHIA / Sep 18, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) today... Read More

Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases Jemperli plus chemotherapy demonstrated a statistically significant and clinically meaningful 31% reduction in risk of death versus chemotherapy alone PHILADELPHIA / Aug 01, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in... Read More

GSK supports annual flu immunization by getting FLULAVAL and FLUARIX to patients in advance of flu season PHILADELPHIA / Jul 11, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and... Read More

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in adults 18+ with data read-outs expected H2 2024 PHILADELPHIA / Jun 07, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) today... Read More

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response New treatment options are needed for patients facing negative impacts to quality-of-life with current standard of care Additional registrational studies of dostarlimab-gxly in dMMR/microsatellite instability-high rectal (MSI-H) and colorectal cancer are recruiting PHILADELPHIA / Jun... Read More

DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free survival (PFS) Median PFS not yet reached at 21.8 months median follow-up versus 12.7 months in bortezomib combination Second trial to show robust efficacy for a belantamab mafodotin combination versus a standard of care in second line and later relapsed/refractory multiple myeloma Results... Read More

Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis GSK to participate in Series C Extension with equity investment Series C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG , a multi-asset, clinical stage biopharmaceutical company focusing on research and... Read More

Dostarlimab-gxly plus chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival (OS) in the overall population 31% reduction in risk of death and 16.4-month improvement in median OS observed with dostarlimab-gxly plus chemotherapy versus chemotherapy in the overall population 37% reduction in risk of disease progression or death and 6-month improvement... Read More

Under its COiMMUNITY Initiative, GSK is committing up to $2 million in 2024 to support adult immunization and health equity GSK launches new patient-centered resources to facilitate provider-patient vaccination conversations and recommendations New Q3 2023 Vaccine Track data show potential return of adult immunization rates to pre-pandemic levels, largely driven by an increase in Medicare and Medicaid claims PHILADELPHIA /... Read More

Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population Adults aged 50 and above with underlying medical conditions are at increased risk for RSV disease 1,2,3 GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk US FDA has set a Prescription Drug User Fee Act action date... Read More

Multi-year collaboration allows GSK to leverage Elegen’s cell-free synthetic DNA production technology. Agreement provides Elegen up to $35 million in near-term financial and development support and fees, in addition to sales of ENFINIA ™ DNA and a potential equity investment in Elegen by GSK. SAN CARLOS, Calif. / Jan 24, 2024 / Business Wire / Elegen, a leader in DNA manufacturing innovation, today announced a collaboration... Read More

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway AIO-001 could redefine the standard-of-care with dosing every six months AIO-001 has potential to expand GSK’s respiratory biologics portfolio to reach a broader portion of asthma patients SAN FRANCISCO & LONDON / Jan 09, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) and... Read More

Ten projects will receive funding to help address adult immunization gaps in communities across the country GSK launched the COiMMUNITY Initiative in June to help increase adult immunization rates in the US through grant funding, increased data transparency and resource-sharing opportunities PHILADELPHIA / Dec 12, 2023 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced the recipients of the inaugural grant program of... Read More

GSK launches Mapping Myelofibrosis to help chart course for those affected by the disease. Myelofibrosis is a complex blood cancer that impacts nearly 25,000 people in the U.S. PHILADELPHIA / Nov 13, 2023 / Business Wire / GSK plc (LSE/NYSE: GSK) has partnered with former Queer Eye star and interior designer Thom Filicia to launch Mapping Myelofibrosis , a new health education initiative aiming to help those impacted by... Read More

Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older Adults aged 50 and above with certain underlying medical conditions are at increased risk for RSV disease 1 GSK is on track to be the first company to submit data in this population to regulators, with decisions on potential label expansion expected in 2024... Read More

Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease, and over 30% will discontinue treatment due to anemia 1,2,3 Ojjaara addresses key manifestations of myelofibrosis, namely anemia, constitutional symptoms and splenomegaly LONDON / Sep 15, 2023 / Business Wire / GSK plc (LSE/NYSE:... Read More

Four events will convene public health leaders and older adults in major cities across the US as they take part in community conversations about Respiratory Syncytial Virus (RSV) Earvin “Magic” Johnson will be joined by healthcare professionals and patient advocates to educate and raise awareness on the risk of RSV infection... Read More

Ahead of the fall and winter RSV season, AREXVY is now widely available in major retail pharmacies and anticipated to be covered by most Medicare and commercial insurance plans PHILADELPHIA / Aug 17, 2023 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced that AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is now available in the US at all major retail pharmacies. In June, the Advisory Committee on... Read More

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face significant unmet need and typically experience poor long-term outcomes with the current standard of care LONDON / Jul 31, 2023 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA)... Read More

GSK supports annual flu immunization with its shipping of FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT PHILADELPHIA / Jul 13, 2023 / Business Wire / GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season. This immediately follows a licensing and lot-release approval from the US Food and... Read More

Launch is planned in the US before the 2023 RSV season Committee recommendations mean over 55 million older adults in the US could have access to RSV vaccination for the first time 1 RSV causes approximately 177,000 hospitalizations and 14,000 deaths in adults aged 65 years and older in the US each year 2,3,4 PHILADELPHIA /... Read More

New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions Safety and reactogenicity data were consistent with initial results from the phase III program The clinical development program will continue to evaluate longer term follow up and the optimal timing... Read More

“I Never Thought to Ask: A Mom’s Quest for Answers” with Soleil Moon Frye, Brought to you by GSK, is a short film that aims to raise awareness about meningitis B and vaccination. View the short film and promotional videos featuring survivors and families affected by meningitis B at myLifetime.com/Ask2BSure PHILADELPHIA / Jun 20, 2023 / Business Wire / GSK plc (LSE/NYSE: GSK) announced today the launch of a new short film in... Read More

Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on adult immunization and health equity Increased data transparency and information on adult immunization trends will be available through enhanced Vaccine Track capabilities and collaborations to better inform public health efforts New resources and tools will help implement tangible solutions and... Read More

Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe... Read More

PHILADELPHIA / Mar 14, 2023 / Business Wire / GSK plc (LSE/NYSE: GSK) has partnered with Earvin “Magic” Johnson to launch Sideline RSV , a new health education campaign aimed to help older adults and their loved ones better understand the risks and potential seriousness of RSV infection and how to help protect themselves. RSV is a common, contagious, and potentially serious respiratory virus. 1,2 It is typically mild and can... Read More

48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response, transfusion independence and splenic response in the majority of patients who responded to treatment during first 24 weeks Additional analyses from MOMENTUM suggest that transfusion independence at week 24 was associated with overall survival PHILADELPHIA--( BUSINESS WIRE )-- GSK plc (LSE/NYSE:GSK) today announced new... Read More